UK markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.31000.0000 (0.00%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.3100
Open1.3300
Bid1.2700 x 3000
Ask1.2900 x 1200
Day's range1.2700 - 1.3300
52-week range1.1500 - 3.4300
Volume124,061
Avg. volume69,812
Market cap265.654M
Beta (5Y monthly)1.33
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    DBV Technologies to Participate in Upcoming Investor Conference

    Montrouge, France, November 22, 2022 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022. Daniel Tassé, Chief Executive Officer, will participate in a Fireside Chat session on Wednesday, Nov. 30, at 8 a.m. ET, as well as one-on-one invest

  • Globe Newswire

    DBV Technologies to Highlight New Clinical Data at ACAAI 2022

    Montrouge, France, November 9, 2022 DBV Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new clinical data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers ages 1 to 3 years will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held November 10-14,

  • Globe Newswire

    DBV Technologies Reports Third Quarter Financial Results and Business Update

    Montrouge, France, November 3, 2022 DBV Technologies Reports Third Quarter Financial Results and Business Update DBV closes Q3 with a cash balance of $213MDBV continues to practice budget discipline measures; cash used in operating activities decreased more than 35% between the nine months ended September 30, 2021, and 2022DBV continues to engage with the U.S. Food and Drug Administration (FDA) regarding the partial clinical hold on the VITESSE Phase 3 clinical study DBV Technologies (Euronext: